Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Teva Pharmaceutical ( (TEVA) ) just unveiled an update.
On December 10, 2025, Teva Pharmaceutical Industries Limited announced that it has obtained consent from its lenders to extend the maturity date of its Revolving Facility Agreement from April 29, 2027, to April 29, 2028. The amendment also includes changes to financial covenants, such as the maximum permitted leverage ratio and conditions related to Investment Grade Status, which could impact the company’s financial flexibility and operational strategy.
The most recent analyst rating on (TEVA) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Teva Pharmaceutical stock, see the TEVA Stock Forecast page.
Spark’s Take on TEVA Stock
According to Spark, TipRanks’ AI Analyst, TEVA is a Neutral.
Teva’s overall stock score reflects a company in transition. Strong technical momentum and positive earnings call insights are offset by financial challenges and valuation concerns. Continued focus on debt reduction and profitability improvement is crucial for future stability.
To see Spark’s full report on TEVA stock, click here.
More about Teva Pharmaceutical
Teva Pharmaceutical Industries Limited operates in the pharmaceutical industry, focusing on the development, production, and marketing of generic and specialty medicines. It is a global leader in generic pharmaceuticals and has a significant presence in the healthcare market.
Average Trading Volume: 11,343,851
Technical Sentiment Signal: Buy
Current Market Cap: $33.02B
See more insights into TEVA stock on TipRanks’ Stock Analysis page.